Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.29)
# 3,424
Out of 4,837 analysts
58
Total ratings
38.71%
Success rate
-10.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMCL Omnicell | Upgrades: Overweight | $31 → $35 | $28.78 | +21.61% | 15 | May 14, 2025 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $10 → $8 | $7.34 | +8.99% | 3 | May 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $8 → $7 | $3.97 | +76.32% | 8 | Apr 29, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $101.18 | +23.54% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $53.00 | +3.77% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $3.94 | +153.81% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $7.55 | +98.68% | 3 | Jan 13, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $275 → $285 | $240.78 | +18.37% | 5 | Dec 6, 2024 |
Omnicell
May 14, 2025
Upgrades: Overweight
Price Target: $31 → $35
Current: $28.78
Upside: +21.61%
Teladoc Health
May 8, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $7.34
Upside: +8.99%
GoodRx Holdings
Apr 29, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.97
Upside: +76.32%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $101.18
Upside: +23.54%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $53.00
Upside: +3.77%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $3.94
Upside: +153.81%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $7.55
Upside: +98.68%
Veeva Systems
Dec 6, 2024
Maintains: Overweight
Price Target: $275 → $285
Current: $240.78
Upside: +18.37%